{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-041225","form_type":"8-K","ticker":"IONS","cik":"0000874015","company_name":"IONIS PHARMACEUTICALS INC","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.421621+00:00","generated_at":"2026-05-16T22:49:14.890327+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ionis reports Phase 3 olezarsen results: 72% TG reduction, 85% fewer pancreatitis events","bullets":["Primary endpoint met: up to 72% placebo-adjusted mean reduction in fasting triglycerides at 6 months, sustained through 12 months (p<0.001).","85% reduction in acute pancreatitis events (p<0.001); 86% of patients achieved TG <500 mg/dL, below risk threshold.","Favorable safety profile; serious AEs lower in olezarsen (9-11%) vs placebo (14%); most common AE mild injection site reactions.","sNDA for 50 mg and 80 mg doses to be submitted to FDA by end of 2025; PDUFA target action date in 2026.","Data presented at AHA Scientific Sessions and simultaneously published in The New England Journal of Medicine."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-041225","json":"https://secwatch.observer/filing/0001140361-25-041225.json","markdown":"https://secwatch.observer/filing/0001140361-25-041225.md","text":"https://secwatch.observer/filing/0001140361-25-041225.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874015/000114036125041225/0001140361-25-041225-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874015/000114036125041225/ef20058520_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:49:14.890327+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}